The patients randomized to the interventional arm will be eligible for two cycles of 7.4GBq 177 Lu-PSMA-I&T at a 6-week interval. After both cycles, patients are monitored every 3weeks (including adverse events, QoL- and xerostomia questionnaires and laboratory testing) at the outpatient ...